Geode Capital Management LLC recently announced the acquisition of new stake in eFFECTOR Therapeutics Inc (NASDAQ:EFTR). The institutional investor has increased its shareholding in the Healthcare company by 151.24% to 0.26 million shares with purchase of 0.16 million shares. This fresh investment now brings its stake to 0.41% valued currently at $0.14 million. In addition, Sonora Investment Management Grou raised its holdings by 0.12 million to 0.12 million shares. And Susquehanna Financial Group LLLP has lifted its position by 4.82% or 2271.0 shares – to 49392.0 shares.
With over 11.31 million eFFECTOR Therapeutics Inc (EFTR) shares trading Tuesday and a closing price of $0.44 on the day, the dollar volume was approximately $4.98 million. The shares have shown a negative half year performance of -48.25% and its price on 01/09/24 lost nearly -19.87%. Currently, there are 64.62M common shares owned by the public and among those 46.32M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 55,566 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in eFFECTOR Therapeutics Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.3 million shares of the company’s stock, all valued at over $0.16 million. Vanguard Extended Market Index Fu bought 0.13 million shares to see its total holdings expand to 0.23 million shares valued at over $0.12 million and representing 0.35% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.33% of the shares outstanding.
Shares of eFFECTOR Therapeutics Inc (NASDAQ: EFTR) opened at $0.4097, down -$0.14 from a prior closing price of $0.55. However, the script later moved the day high at 0.5360, down -19.87%. The company’s stock has a 5-day price change of -9.69% and -23.88% over the past three months. EFTR shares are trading -5.33% year to date (YTD), with the 12-month market performance down to -11.50% lower. It has a 12-month low price of $0.34 and touched a high of $1.48 over the same period. EFTR has an average intraday trading volume of 1.86 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.44%, -15.53%, and -28.94% respectively.
Institutional ownership of eFFECTOR Therapeutics Inc (NASDAQ: EFTR) shares accounts for 10.48% of the company’s 64.62M shares outstanding. Mutual fund holders own 37.97%, while other institutional holders and individual stakeholders account for 9.13% and 1.35% respectively.
It has a market capitalization of $28.59M and a beta (3y monthly) value of 0.35. The earnings-per-share (ttm) stands at -$0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.95% over the week and 12.94% over the month.
Analysts forecast that eFFECTOR Therapeutics Inc (EFTR) will achieve an EPS of -$0.12 for the current quarter, -$0.11 for the next quarter and -$0.44 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.14 while analysts give the company a high EPS estimate of -$0.1. Comparatively, EPS for the current quarter was -$0.22 a year ago. Earnings per share for the fiscal year are expected to decrease by -13.94%, and 29.26% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate eFFECTOR Therapeutics Inc (EFTR) as a “Strong Buy” at a consensus score of 1.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the EFTR, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on January 25, 2022, with the firm’s price target at $20-$6.20.
